Nanoemulsion Drug Delivery: New Path For Bedaquiline

A recent study has introduced nanoemulsion-based drug delivery as a promising method for administering the oral drug bedaquiline (BDQ) with high loading efficiency as a liquid dosage form, according to the authors. Bedaquiline is a diarylquinoline drug used to treat multidrug-resistant tuberculosis, currently available only in tablet form, which poses challenges for pediatric administration. By leveraging nanoemulsion-based drug delivery, this study represents the first application of nanoemulsions for BDQ, emphasizing the potential benefits for drug solubility, delivery, and patient convenience.

Key Findings from the Nanoemulsion Formulation Study

Nanoemulsion-based drug delivery has been gaining attention in recent years, particularly in the field of lipid-based nanocarrier formulations for oral administration. Due to the “highly lipophilic” properties of BDQ, it is an ideal candidate for nanoemulsion-based drug delivery systems. In vitro studies revealed that the BDQ-loaded nanoemulsion achieved a 97.5% drug release within 24 hours, while the pure drug form showed “no detectable release” under identical conditions. This suggests a significantly enhanced release profile with nanoemulsion-based drug delivery.

Researchers used a self-emulsification method to successfully formulate BDQ into a nanoemulsion using three different solvents, demonstrating that varying surfactant concentrations did not significantly impact the drug’s content. This method proved effective, reinforcing the potential of nanoemulsion-based drug delivery as a viable carrier for BDQ and similar drugs with challenging solubility profiles.

Future Applications of Nanoemulsion-Based Drug Delivery

With these promising findings, the optimized BDQ nanoemulsion could serve as a more convenient and user-friendly alternative to the traditional 100 mg BDQ tablet, particularly for children who may struggle with tablet ingestion. The manufacturing process for the nanoemulsion is noted as straightforward and adaptable for industrial-scale production, making it a feasible option for wider implementation in the pharmaceutical industry.

However, further studies are recommended to enhance drug content maximization and evaluate the therapeutic efficacy of the nanoemulsions against multi-drug-resistant tuberculosis. Still, this innovative nanoemulsion-based drug delivery method shows strong potential for improving the solubility, delivery, and administration of BDQ, possibly broadening the reach and effectiveness of tuberculosis treatments.